Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Novartis
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
BeiGene
MorphoSys AG
Washington University School of Medicine
Merck Sharp & Dohme LLC
Vanderbilt-Ingram Cancer Center
Case Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center